Credit Industriel ET Commercial Acquires Shares of 240,000 Amicus Therapeutics, Inc. $FOLD

Credit Industriel ET Commercial acquired a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 240,000 shares of the biopharmaceutical company’s stock, valued at approximately $3,418,000.

A number of other hedge funds also recently bought and sold shares of FOLD. Vestal Point Capital LP lifted its position in shares of Amicus Therapeutics by 178.4% in the second quarter. Vestal Point Capital LP now owns 11,900,000 shares of the biopharmaceutical company’s stock worth $68,187,000 after purchasing an additional 7,625,000 shares in the last quarter. UBS Group AG lifted its position in shares of Amicus Therapeutics by 240.5% in the fourth quarter. UBS Group AG now owns 5,893,288 shares of the biopharmaceutical company’s stock worth $83,920,000 after purchasing an additional 4,162,433 shares in the last quarter. Qube Research & Technologies Ltd lifted its position in shares of Amicus Therapeutics by 223.9% in the second quarter. Qube Research & Technologies Ltd now owns 3,466,911 shares of the biopharmaceutical company’s stock worth $19,865,000 after purchasing an additional 2,396,410 shares in the last quarter. State Street Corp lifted its position in shares of Amicus Therapeutics by 21.5% in the second quarter. State Street Corp now owns 11,568,097 shares of the biopharmaceutical company’s stock worth $66,285,000 after purchasing an additional 2,049,078 shares in the last quarter. Finally, Iron Triangle Partners LP purchased a new stake in shares of Amicus Therapeutics in the third quarter worth approximately $15,534,000.

Insider Buying and Selling

In related news, CEO Bradley L. Campbell sold 22,500 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $14.35, for a total value of $322,875.00. Following the transaction, the chief executive officer owned 998,680 shares in the company, valued at approximately $14,331,058. This represents a 2.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 2.20% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on FOLD shares. Zacks Research lowered shares of Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Amicus Therapeutics in a research report on Friday, March 27th. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $14.50 price target (down from $16.00) on shares of Amicus Therapeutics in a research report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $14.56.

Amicus Therapeutics Price Performance

NASDAQ FOLD opened at $14.49 on Wednesday. The company has a 50 day simple moving average of $14.42 and a 200-day simple moving average of $12.77. The company has a debt-to-equity ratio of 1.43, a current ratio of 2.84 and a quick ratio of 1.88. The firm has a market capitalization of $4.55 billion, a price-to-earnings ratio of -181.13 and a beta of 0.48. Amicus Therapeutics, Inc. has a 52-week low of $5.51 and a 52-week high of $14.50.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Friday, February 20th. The biopharmaceutical company reported $0.10 EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.03). Amicus Therapeutics had a positive return on equity of 4.15% and a negative net margin of 4.27%.The firm had revenue of $185.21 million during the quarter, compared to analyst estimates of $185.00 million. During the same quarter in the prior year, the company posted $0.09 EPS. The company’s quarterly revenue was up 23.7% on a year-over-year basis. Equities research analysts predict that Amicus Therapeutics, Inc. will post 0.43 earnings per share for the current fiscal year.

Amicus Therapeutics Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure?based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.